Stay updated on Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.

Latest updates to the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates regarding a clinical trial for Pembrolizumab in treating high-risk cutaneous squamous cell carcinoma of the head and neck, including the addition of detailed trial objectives and inclusion criteria, while removing previous descriptions of the cancer's aggressiveness and treatment context.SummaryDifference48%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.